Eli Lilly and Company $LLY Stock: N10 Assets LLC Grows Position

N10 Assets LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 14.9% during the 3rd quarter, Holdings Channel.com reports. The fund owned 4,676 shares of the company’s stock after buying an additional 606 shares during the period. Eli Lilly and Company accounts for 2.0% of N10 Assets LLC’s investment portfolio, making the stock its 19th biggest holding. N10 Assets LLC’s holdings in Eli Lilly and Company were worth $5,411,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Generate Investment Management Ltd boosted its holdings in Eli Lilly and Company by 8.4% in the third quarter. Generate Investment Management Ltd now owns 57,065 shares of the company’s stock valued at $66,029,000 after purchasing an additional 4,409 shares in the last quarter. WestHill Financial Advisors Inc. purchased a new position in Eli Lilly and Company in the third quarter valued at approximately $485,000. MinichMacGregor Wealth Management LLC increased its stake in Eli Lilly and Company by 19.8% in the third quarter. MinichMacGregor Wealth Management LLC now owns 968 shares of the company’s stock valued at $1,120,000 after purchasing an additional 160 shares during the last quarter. First Citizens Bank & Trust Co. raised its holdings in Eli Lilly and Company by 22.3% during the third quarter. First Citizens Bank & Trust Co. now owns 38,512 shares of the company’s stock worth $44,561,000 after purchasing an additional 7,019 shares in the last quarter. Finally, Focus Financial Network Inc. raised its holdings in Eli Lilly and Company by 9.0% during the third quarter. Focus Financial Network Inc. now owns 7,646 shares of the company’s stock worth $8,847,000 after purchasing an additional 632 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY traded up $45.27 during trading on Wednesday, hitting $1,211.78. 1,446,274 shares of the stock were exchanged, compared to its average volume of 2,944,073. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 1-year low of $783.85 and a 1-year high of $1,292.65. The stock has a fifty day moving average price of $1,176.60 and a two-hundred day moving average price of $1,102.08. The firm has a market capitalization of $1.14 trillion, a P/E ratio of 40.67, a PEG ratio of 1.52 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company’s revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the company earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 34.79 earnings per share for the current year.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts are increasingly focused on retatrutide, Lilly’s next-generation obesity treatment, which could become a larger growth driver than Zepbound if clinical results and regulatory progress remain favorable. Investors may view the drug as helping extend Lilly’s leadership in the fast-growing cardiometabolic market. Eli Lilly Reports Earnings on Oct. 29. Here’s Why the Retatrutide Story Matters More Than the Quarter
• Positive Sentiment: Erste Group Bank modestly raised its FY2026 and FY2027 earnings-per-share estimates to $36.55 and $47.30, respectively. The upward revisions reinforce expectations for continued earnings momentum, with the FY2026 estimate also above the broader consensus cited in the report. Eli Lilly earnings estimate revisions
• Positive Sentiment: Lilly reported progress in a Phase 1 food-effect study of tersolisib (LY406480), providing another incremental update from its development pipeline. The study is early stage, but continued clinical activity can support confidence that Lilly is building growth opportunities beyond its current blockbuster medicines. Lilly’s Tersolisib Food-Effect Study Marks Quiet But Important Pipeline Progress
• Positive Sentiment: Lilly’s collaboration with Prelude Therapeutics will evaluate the experimental KAT6A degrader PRT13722 in combination with breast-cancer therapies, with Phase 1 enrollment expected to begin in the fourth quarter of 2026. The partnership expands Lilly’s oncology pipeline, though commercial impact is distant. Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly
• Neutral Sentiment: Investors are preparing for Lilly’s October 29 quarterly report, with analysts expecting continued earnings growth. The results, guidance and management commentary on Zepbound, retatrutide and manufacturing capacity could be more important than the quarter’s headline numbers. Eli Lilly and Company Earnings Preview: What to Expect
• Negative Sentiment: A study of a drug combination that produced greater weight loss than Zepbound also showed substantially higher discontinuation rates, highlighting tolerability and adherence risks for future obesity treatments. Lilly’s premium valuation leaves the stock sensitive to disappointing clinical or earnings news. Drug combination generated more weight loss but higher discontinuation rates

Insider Activity

In related news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock valued at $15,958,170 in the last ninety days. 0.14% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, August 26th. Leerink Partners upped their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Guggenheim increased their target price on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research report on Friday, September 18th. Bank of America lifted their price target on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Finally, Citigroup lifted their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,313.43.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.